| GlycoEra–Roche: investment, 202111 financing round Series A totalling CHF45m incl co-lead investor Roche Venture Fund |
2021-11-05 |
| GlycoEra–SEVERAL: investment, 202111 financing round Series A CHF45m co-led by 5AM Ventures + RVF + Sofinnova Partners |
2021-11-05 |
| GlycoEra–Sofinnova: investment, 202111 financing round Series A totalling CHF45m incl co-lead investor Sofinnova Partners |
2021-11-05 |
| GlycoEra–Trophic Communications: public relations, 202111 service existent by Trophic Communications |
2021-11-05 |
| Life Sciences Partners–SEVERAL: investment, –202111–202202 final closing of LSP 7 fund at hard cap of €1b |
2021-11-04 |
| Mainz Biomed–SEVERAL: investment, 202111 IPO $10m with 2m common shares at $5/share at Nasdaq Capital Market |
2021-11-04 |
| Roche–Novartis: investment, 202111 repurchase of total equity stake held by Novartis for CHF19b by Roche |
2021-11-04 |
| Cube Biotech–ArchiMed: investment, 202111 acquisition of majority stake by ArchiMed with founders remaining significant shareholders |
2021-11-03 |
| Insilico Biotechnology–Yokogawa: investment, 202111 acquisition 100% of Insilico Biotechnology AG by Yokogawa Electric Corp |
2021-11-02 |
| Capstan Therapeutics–Novartis: investment, 202111 seed financing round totalling $63m incl co-lead investor Novartis Venture Fund |
2021-11-01 |
| Capstan Therapeutics–SEVERAL: investment, 202111 seed financing round $63m led by NVF + OrbiMed |
2021-11-01 |
| LenioBio–Bridford Group: investment, 202111 financing round Series A extension totalling €11.5m incl existing + lead investor Bridford Group |
2021-11-01 |
| LenioBio–SEVERAL: investment, 202111 financing round Series A extension €11.5m led by Bridford Group |
2021-11-01 |
| Sanming Minhe Pharmaceutical Technology–Enzymaster: investment, 202111 acquisition of Sanming Minhe by Enzymaster |
2021-11-01 |
| Pan Cancer T–Akampion: public relations, 202111 service existent by Akampion |
2021-10-28 |
| Immunai–SEVERAL: investment, 202110 financing round Series B $215m led by Koch Disruptive Technologies |
2021-10-27 |
| Noxxon–LifeSci: public relations, 202110 service existent LifeSci Advisors is investor/media relations contact |
2021-10-27 |
| Sartorius–Waters: biopharma production technology, 202110– collab product integration BioAccord LC-MS as bioprocess analyzer with Ambr bioreactor |
2021-10-27 |
| Ajinomoto–Insilico Biotechnology: biopharma production technology, 202110– collab using digital twins to develop cell culture processes w Genexine |
2021-10-26 |
| DNA Script–Merck (DE): investment, 202110 financing round Series C totalling $165m incl existing + co-investor M Ventures |
2021-10-26 |
| DNA Script–SEVERAL: investment, 202110 financing round Series C $165m co-led by Coatue Management + Catalio Capital Management |
2021-10-26 |
| Exciva–Andera Partners: investment, 202110 financing round Series A totalling €9m incl lead investor Andera Partners |
2021-10-26 |
| Exciva–Cure8: investment, 202110 financing round Series A totalling €9m incl co-investor Cure8 |
2021-10-26 |
| Exciva–LBBW: investment, 202110 financing round Series A totalling €9m incl co-investor LBBW Venture Capital |
2021-10-26 |
| Exciva–SEVERAL: investment, 202110 financing round Series A €9m led by Andera Partners |
2021-10-26 |
| Valneva–SEVERAL: investment, 202110 private placement €76m of ordinary shares) at €17/share outside of US |
2021-10-26 |
| Valneva–SEVERAL: investment, 202110 public offering $653k+$13.3m of ADSs (each 2 ordinary shares) at $39.42/ADS in US |
2021-10-26 |
| Ariceum Therapeutics–Ipsen: investment, 202010 Ipsen became shareholder by selling rights to satoreotide to Ariceum (then SatoSea Oncology GmbH) |
2021-10-22 |
| Ariceum Therapeutics–Ipsen: satoreotide, 202010 acquisition of all rights from Ipsen which became shareholder of Ariceum (then SatoSea Oncology GmbH) |
2021-10-22 |
| Emergence Therapeutics–Mablink Bioscience: ADC technology, 202110– license for use of PSARlink drug-linker to develop ADC targeting Nectin-4 |
2021-10-21 |
| Leucid Bio–2Invest: investment, 202110 financing round Series A totalling £11.5m incl new + co-investor 2InvestAG |
2021-10-21 |
| Leucid Bio–SEVERAL: investment, 202110 financing round Series A £11.5m led by Epidarex + Vulpes Investment Management |
2021-10-21 |
| InflaRx–Germany (govt): grant, 202110– grant up to €43.7m from BMBF + BMG for developm of vilobelimab for Covid-19 |
2021-10-19 |
| Roche–Ibex.ai: digital pathology, 202110– collab integration of Galen AI-based cancer dx platform into Roche’s Navify Digital Pathology |
2021-10-18 |
| Abalos Therapeutics–SEVERAL: investment, 202110 financing round Series A extension €32.5m led by Seventure Partners |
2021-10-14 |
| Computomics–Amathaon Capital: investment, 202110 acquisition €na of minority stake by Amathaon Capital |
2021-10-14 |
| Computomics–Baden-Württemberg (govt): investment, 202110 existent seed investor MBG Mittelständische Beteiligungsgesellschaft Baden-Württemberg |
2021-10-14 |
| Computomics–BASF: investment, 202110 acquisition €na of minority stake by BASF Venture Capital GmbH |
2021-10-14 |
| UbiSim–Labster: investment, 202110– acquisition of UbiSim by Labster SIGNED |
2021-10-14 |
| VeroVaccines–SEVERAL: investment, 202110 financing round Series B mid-7-figure € from consortium of investors from Germany + Switzerland |
2021-10-14 |
| Creapaper–eCapital: investment, 202110 financing round Series B totalling €20m incl existing investor eCapital |
2021-10-06 |
| Creapaper–EU (govt): investment, 202110 financing round Series B totalling €20m incl new investor EIC Fund |
2021-10-06 |
| Creapaper–JS Capital: investment, 202110 financing round Series B totalling €20m incl new investor JS Capital |
2021-10-06 |
| Creapaper–Ranpak: investment, 202110 financing round Series B totalling €20m incl new investor Ranpak |
2021-10-06 |
| Creapaper–Schusterman Family Investments: investment, 202110 financing round Series B totalling €20m incl new investor Schusterman Family Investments |
2021-10-06 |
| Creapaper–SEVERAL: investment, 202110 financing round Series B €20m |
2021-10-06 |
| Creapaper–Soros Capital: investment, 202110 financing round Series B totalling €20m incl new investor Soros Capital |
2021-10-06 |
| Atbtherapeutics–Trophic Communications: public relations, 202110 service existent by Trophic Communications |
2021-10-05 |
| Cellecta–Merck (DE): CRISPR technology, 202110– license for CRISPR-Cas9 technology to Cellecta |
2021-10-05 |
| Exo Therapeutics–SEVERAL: investment, 202120 financing round Series B $78m lead by new investor Nextech invest |
2021-10-05 |
| iOmx Therapeutics–SEVERAL: investment, 202110 financing round Series B €65m co-led by Athos Service GmbH + MIG Capital AG |
2021-10-05 |
| Pierre Fabre–Atara Biotherapeutics: tabelecleucel, 202110– collab $45m upfront + $320m milestones + royalties excl sales in EMEA for EBV+ cancers |
2021-10-04 |
| Novartis–GSK: cephalosporin, 202110 acquisition of GSK’s global cephalosporins portfoloio by Sandoz |
2021-10-01 |
| QInstruments–Bico: investment, 202110 acquisition 100% cash/debt free for €58.25m upfront + €3m milestones thereof 13% paid in new Bico shares |
2021-10-01 |
| Roche–PathAI: AI-based diagnostics, 202110 initial collab |
2021-10-01 |
| Advent France Biotechnology–Boehringer: investment, 202109 first closing totalling €86m of AFB Fund II incl investor BI Venture Fund |
2021-09-30 |
| Advent France Biotechnology–SEVERAL: investment, 202109 first closing €86m of AFB Fund II |
2021-09-30 |
| Isarna Therapeutics–Trophic Communications: public relations, 202109 service existent by Trophic Communications |
2021-09-30 |
| Applied Microarrays–Schott: investment, 202109–202110 acquisition of AMI by Schott Minifab |
2021-09-28 |
| Hadean Ventures–SEVERAL: investment, 202109 first closing of Hadean Capital I fund at €90m |
2021-09-27 |
| Thermo Fisher–Carbon Engineering: analytical technology, 202109 collab existent direct air capture technology to reduce CO2 emissions |
2021-09-23 |
| Hexagon Bio–Nextech: investment, 202109 financing round totalling $61m incl new + lead investor Nextech Invest |
2021-09-22 |
| Hexagon Bio–SEVERAL: investment, 202109 financing round $61m led by Nextech Invest |
2021-09-22 |
| Univ Aarhus–Novo Group: grant, 202109–202808 grant DKK630m (€84.7m) to establish NNF CO2 Research Center at AU + six satellite institutes |
2021-09-22 |
| Arctos Medical–Novartis: investment, 202109 acquisition by Novartis |
2021-09-21 |
| Biotest–Grifols: investment, 202109–202204 public cash tender offer €895m for remaining 54.5% of shares at €34/ordinary share + €37/preferred share |
2021-09-17 |
| Creat (CN)–Grifols: investment, 202109 acquisition 100% of Tiancheng Germany owning 90% voting rights + 45% total capital of Biotest for €773m cash |
2021-09-17 |
| Anjarium Biosciences–Abingworth: investment, 202109 financing round Series A totalling CHF55.5m incl co-lead investor Abingworth |
2021-09-16 |
| Anjarium Biosciences–Citadel: investment, 202109 financing round Series A totalling CHF55.5m incl co-investor Surveyor Capital |
2021-09-16 |
| Anjarium Biosciences–Gimv: investment, 202109 financing round Series A totalling CHF55.5m incl co-lead investor Gimv |
2021-09-16 |
| Anjarium Biosciences–Huntsworth: public relations, 202109 service existent by Medistrava Consulting |
2021-09-16 |
| Anjarium Biosciences–Omega Funds: investment, 202109 financing round Series A totalling CHF55.5m incl co-investor Omega Funds |
2021-09-16 |
| Anjarium Biosciences–Pfizer: investment, 202109 financing round Series A totalling CHF55.5m incl co-investor Pfizer Ventures |
2021-09-16 |
| Anjarium Biosciences–SEVERAL: investment, 202109 financing round Series A CHF55.5m ($61m) co-led by Abingworth + Gimv |
2021-09-16 |
| BRAIN Biotech–SEVERAL: investment, 202109 capital increase €19.6m with 1.99m new shares at €9.85/share to institutional investors |
2021-09-15 |
| Evotec–Biognosys: MS-based proteomics, 202109– collab integration of Spectronaut proteomics data analys into drug discovery + clinical proteomics |
2021-09-14 |
| Roche–Temedica: digital companion, –202109 collab developm of digital companion app Brisa for MS patients by Temedica + Roche |
2021-09-14 |
| Boehringer–Twist Bioscience: antibody drug discovery, 202109– collab using Twist Biopharma antibody phage display libraries against Boehringer targets |
2021-09-09 |
| TIB Molbiol–Roche: investment, 202109–202112 acquisition 100% of TIB Mobiol Group by Roche |
2021-09-09 |
| Diaccurate–MC Services: public relations, 202109 service existent by MC Services |
2021-09-08 |
| BMS–Evotec: neurological drug, 202109– license ww excl $20m upfront + $250m milestones + 2-digit royalties for EVT8683/BMS-986419 |
2021-09-02 |
| Broken String Biosciences–SEVERAL: investment, 202109 seed financing round $4m with investors from UK + DE + US |
2021-09-01 |
| ImmunOs Therapeutics–Akampion: public relations, 202109 service existent by Akampion |
2021-09-01 |
| Oviva–Albion Ventures: investment, 202109 financing round Series C totalling $80m incl existing + co-investor AlbionVC |
2021-09-01 |
| Oviva–Earlybird: investment, 202109 financing round Series C totalling $80m incl existing + co-investor Earlybird |
2021-09-01 |
| Oviva–F-Prime: investment, 202109 financing round Series C totalling $80m incl existing + co-investor F-Prime Capital |
2021-09-01 |
| Oviva–Fidelity: investment, 202109 financing round Series C totalling $80m incl existing + co-investor Eight Roads Ventures |
2021-09-01 |
| Oviva–MedTech Innovation Partners: investment, 202109 financing round Series C totalling $80m incl existing + co-investor MTIP |
2021-09-01 |
| Oviva–SEVERAL: investment, 202109 financing round Series C $80m co-led by Sofina + Temasek |
2021-09-01 |
| Oviva–Sofina: investment, 202109 financing round Series C totalling $80m incl co-lead investor Sofina |
2021-09-01 |
| Oviva–Temasek: investment, 202109 financing round Series C totalling $80m incl co-lead investor Temasek |
2021-09-01 |
| Comet Therapeutics–ABP (NL): investment, 202108 existing investor Inkef Capital at time of sale of Comet Tx to VectivBio |
2021-08-31 |
| Comet Therapeutics–Canaan Partners: investment, 202108 existing investor Canaan at time of sale of Comet Tx to VectivBio |
2021-08-31 |
| Comet Therapeutics–Mission BioCapital: investment, 202108 existing investor Mission BioCapital at time of sale of Comet Tx to VectivBio |
2021-08-31 |
| Comet Therapeutics–Sofinnova: investment, 202108 existing investor Sofinnova Partners at time of sale of Comet Tx to VectivBio |
2021-08-31 |
| Comet Therapeutics–VectivBio: investment, 202108–202109 acquisition in cash + shares upfront plus milestones in cash or equity |
2021-08-31 |
| NürnbergMesse–Messe Stuttgart: T4M trade show, 202108 acquisition of T4M event from Messe Stuttgart by MedtecLIVE GmbH |
2021-08-30 |
| Biognosys–ETH Zürich: LiP technology, 202108 collab developm + excl license from Institute of Systems Biology |
2021-08-27 |
| HealthCare Royalty–ADC Therapeutics: antibody-drug conjugates, 202108 acquisition $225m upfront + $100m milestones royalty rights to Zynlonta + Cami |
2021-08-26 |
| Cardior Pharmaceuticals–ABP (NL): investment, 202108 financing round Series B totalling €64m incl new + lead investor Inkef Capital |
2021-08-25 |
![[LSG] Life-Sciences-Germany.com - The Life Sciences Web Portal for German-speaking Europe](/images/basics/lsg-life-sciences-germany-portal-logo.svg){kind=logo}
1 2 3 ... 19 20 21 ... 40 41 42 
Date
![Picture [iito] LSE iitoLifeScience Life Sciences Mass Spec 120x120px](/banner/iito-business-intelligence-20230710-120-120-twitter-iitolifescience-germany-europe-mass-spec.jpg)
![Picture [LSUS] Life-Sciences-USA.com – The Business Web Portal 120x600px](/banner/iito-20181119-120-600-lsus-life-sciences-usa-com.jpg)
